Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

Research output: Contribution to journalJournal articlepeer-review

Standard

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes. / Bergmann, Natasha Chidekel; Lund, Asger; Gasbjerg, Lærke Smidt; Jørgensen, Niklas Rye; Jessen, Lene; Hartmann, Bolette; Holst, Jens Juul; Christensen, Mikkel Bring; Vilsbøll, Tina; Knop, Filip Krag.

In: The Journal of clinical endocrinology and metabolism, Vol. 104, No. 7, 07.2019, p. 2953–2960.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Bergmann, NC, Lund, A, Gasbjerg, LS, Jørgensen, NR, Jessen, L, Hartmann, B, Holst, JJ, Christensen, MB, Vilsbøll, T & Knop, FK 2019, 'Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes', The Journal of clinical endocrinology and metabolism, vol. 104, no. 7, pp. 2953–2960. https://doi.org/10.1210/jc.2019-00008

APA

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019). Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes. The Journal of clinical endocrinology and metabolism, 104(7), 2953–2960. https://doi.org/10.1210/jc.2019-00008

Vancouver

Bergmann NC, Lund A, Gasbjerg LS, Jørgensen NR, Jessen L, Hartmann B et al. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes. The Journal of clinical endocrinology and metabolism. 2019 Jul;104(7):2953–2960. https://doi.org/10.1210/jc.2019-00008

Author

Bergmann, Natasha Chidekel ; Lund, Asger ; Gasbjerg, Lærke Smidt ; Jørgensen, Niklas Rye ; Jessen, Lene ; Hartmann, Bolette ; Holst, Jens Juul ; Christensen, Mikkel Bring ; Vilsbøll, Tina ; Knop, Filip Krag. / Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes. In: The Journal of clinical endocrinology and metabolism. 2019 ; Vol. 104, No. 7. pp. 2953–2960.

Bibtex

@article{516693767249499c9b226ed5375a14e2,
title = "Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes",
abstract = "CONTEXT: The gut-derived incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), have been suggested to play a role in bone metabolism. Exogenous administration of GIP inhibits bone resorption, while the effect of GLP-1 is less clear. Furthermore, the combined effect of exogenous GIP and GLP-1 on bone metabolism is unknown.OBJECTIVE: To investigate the effect of separate and combined infusions of the incretin hormones GIP and GLP-1 on bone resorption and formation.DESIGN: Randomized, double-blinded, placebo-controlled, crossover study including five study days.PARTICIPANTS: Seventeen overweight/obese men.INTERVENTIONS: On the first study day, a 50 g oral glucose tolerance test (OGTT) was performed. On the next four study days, isoglycemic IV glucose infusions (IIGI), mimicking the glucose excursions from the OGTT, were performed with concomitant infusions of GIP (4 pmol/kg/min), GLP-1 (1 pmol/kg/min), GIP+GLP-1 (4 and 1 pmol/kg/min, respectively) or placebo, respectively.PRIMARY OUTCOMES: Changes in bone resorption assessed by measurements of carboxy-terminal type I collagen crosslinks (CTX), and in bone formation as assessed by procollagen type 1 N-terminal propeptide (P1NP) concentrations.RESULTS: During the OGTT, CTX was significantly lowered by 54±13% from baseline (mean±SD) compared to 28±12% during IIGI+saline (P <0.0001). During IIGI+GLP-1 and IIGI+GIP, respectively, CTX was lowered by 65±16% and 74±9% from baseline, while IGII+GIP+GLP-1 lowered CTX by 84±4% from baseline. P1NP levels were unaffected by the interventions.CONCLUSIONS: Our data suggest that GLP-1, like GIP, may be involved in regulation of bone resorption and that GIP and GLP-1 together have partially additive inhibitory effects.",
author = "Bergmann, {Natasha Chidekel} and Asger Lund and Gasbjerg, {L{\ae}rke Smidt} and J{\o}rgensen, {Niklas Rye} and Lene Jessen and Bolette Hartmann and Holst, {Jens Juul} and Christensen, {Mikkel Bring} and Tina Vilsb{\o}ll and Knop, {Filip Krag}",
note = "Copyright {\textcopyright} 2019 Endocrine Society.",
year = "2019",
month = jul,
doi = "10.1210/jc.2019-00008",
language = "English",
volume = "104",
pages = "2953–2960",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

AU - Bergmann, Natasha Chidekel

AU - Lund, Asger

AU - Gasbjerg, Lærke Smidt

AU - Jørgensen, Niklas Rye

AU - Jessen, Lene

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Christensen, Mikkel Bring

AU - Vilsbøll, Tina

AU - Knop, Filip Krag

N1 - Copyright © 2019 Endocrine Society.

PY - 2019/7

Y1 - 2019/7

N2 - CONTEXT: The gut-derived incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), have been suggested to play a role in bone metabolism. Exogenous administration of GIP inhibits bone resorption, while the effect of GLP-1 is less clear. Furthermore, the combined effect of exogenous GIP and GLP-1 on bone metabolism is unknown.OBJECTIVE: To investigate the effect of separate and combined infusions of the incretin hormones GIP and GLP-1 on bone resorption and formation.DESIGN: Randomized, double-blinded, placebo-controlled, crossover study including five study days.PARTICIPANTS: Seventeen overweight/obese men.INTERVENTIONS: On the first study day, a 50 g oral glucose tolerance test (OGTT) was performed. On the next four study days, isoglycemic IV glucose infusions (IIGI), mimicking the glucose excursions from the OGTT, were performed with concomitant infusions of GIP (4 pmol/kg/min), GLP-1 (1 pmol/kg/min), GIP+GLP-1 (4 and 1 pmol/kg/min, respectively) or placebo, respectively.PRIMARY OUTCOMES: Changes in bone resorption assessed by measurements of carboxy-terminal type I collagen crosslinks (CTX), and in bone formation as assessed by procollagen type 1 N-terminal propeptide (P1NP) concentrations.RESULTS: During the OGTT, CTX was significantly lowered by 54±13% from baseline (mean±SD) compared to 28±12% during IIGI+saline (P <0.0001). During IIGI+GLP-1 and IIGI+GIP, respectively, CTX was lowered by 65±16% and 74±9% from baseline, while IGII+GIP+GLP-1 lowered CTX by 84±4% from baseline. P1NP levels were unaffected by the interventions.CONCLUSIONS: Our data suggest that GLP-1, like GIP, may be involved in regulation of bone resorption and that GIP and GLP-1 together have partially additive inhibitory effects.

AB - CONTEXT: The gut-derived incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), have been suggested to play a role in bone metabolism. Exogenous administration of GIP inhibits bone resorption, while the effect of GLP-1 is less clear. Furthermore, the combined effect of exogenous GIP and GLP-1 on bone metabolism is unknown.OBJECTIVE: To investigate the effect of separate and combined infusions of the incretin hormones GIP and GLP-1 on bone resorption and formation.DESIGN: Randomized, double-blinded, placebo-controlled, crossover study including five study days.PARTICIPANTS: Seventeen overweight/obese men.INTERVENTIONS: On the first study day, a 50 g oral glucose tolerance test (OGTT) was performed. On the next four study days, isoglycemic IV glucose infusions (IIGI), mimicking the glucose excursions from the OGTT, were performed with concomitant infusions of GIP (4 pmol/kg/min), GLP-1 (1 pmol/kg/min), GIP+GLP-1 (4 and 1 pmol/kg/min, respectively) or placebo, respectively.PRIMARY OUTCOMES: Changes in bone resorption assessed by measurements of carboxy-terminal type I collagen crosslinks (CTX), and in bone formation as assessed by procollagen type 1 N-terminal propeptide (P1NP) concentrations.RESULTS: During the OGTT, CTX was significantly lowered by 54±13% from baseline (mean±SD) compared to 28±12% during IIGI+saline (P <0.0001). During IIGI+GLP-1 and IIGI+GIP, respectively, CTX was lowered by 65±16% and 74±9% from baseline, while IGII+GIP+GLP-1 lowered CTX by 84±4% from baseline. P1NP levels were unaffected by the interventions.CONCLUSIONS: Our data suggest that GLP-1, like GIP, may be involved in regulation of bone resorption and that GIP and GLP-1 together have partially additive inhibitory effects.

U2 - 10.1210/jc.2019-00008

DO - 10.1210/jc.2019-00008

M3 - Journal article

C2 - 30848791

VL - 104

SP - 2953

EP - 2960

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -

ID: 214747404